カラリス・セラピューティクス
Kalaris Therapeutics Inc
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), as well as for the treatment of other exudative and neovascular retinal diseases.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | -0.48 | $0 | -$11M |
| 2026 Q1 | -0.46 | $0 | -$13M |
| 2025 Q4 | -0.44 | $0 | -$9M |
| 2025 Q3 | -0.64 | $0 | -$12M |
| 2025 Q2 | -0.61 | $0 | -$15M |
| 2025 Q1 | -2.52 | $0 | -$7M |
| 2024 Q4 |
| -3.64 |
| $0 |
| — |
| 2024 Q3 | -7.64 | $0 | -$4M |